Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
the market for a controversial treatment that still hasn't proved its benefit in clinical trials. Most Read from Bloomberg Car Dealerships Across US Halt Services After Cyberattack CDK Tells Car Dealers Their Systems Likely Offline Several Days Putin's Hybrid War Opens a Second Front on NATO's Eastern Border Hedge Fund Talent Schools Are Looking for the Perfect Trader United Airlines Jet Turns Back After Engine Piece Falls Off Sarepta shares surged 36% in extended trading at 5:51 p.m. in New York. The drug's approval was widened for use in patients who are at least 4 years of age with Duchenne muscular dystrophy, Sarepta said in a statement. The agency granted a traditional approval for patients who can still walk. It also granted an accelerated approval for patients who can't walk, meaning the company will need to perform a confirmatory trial. The therapy, called Elevidys, has highlighted a type of approval that's become the center of debate. The treatment, which is
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Is Pfizer Inc. (PFE) the Best Healthcare Stock to Buy Under $50? [Yahoo! Finance]Yahoo! Finance
- Global Panic Disorders Market Size To Exceed USD 15.42 Billion By 2033 | CAGR of 4.73% [Yahoo! Finance]Yahoo! Finance
- Daily Dividend Report: AT&T, Kroger, Matson, Pfizer, Edison [Forbes]Forbes
- This Recent FDA Approval Is Bad News for Pfizer [Yahoo! Finance]Yahoo! Finance
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/11/24 - Form 11-K
- PFE's page on the SEC website